CASCADE: Lung Cancer Screening With Low-dose CT Scan in Women : Implementation Study

Sponsor
Assistance Publique - Hôpitaux de Paris (Other)
Overall Status
Recruiting
CT.gov ID
NCT05195385
Collaborator
Ministère de la Santé et des Solidarités (Other), National Cancer Institute, France (Other)
2,400
1
1
30
79.9

Study Details

Study Description

Brief Summary

The purpose of this study is to determine whether reading of low-dose thoracic CT scans can be done by a single general radiologist who has been trained to lung cancer screening, and will evaluate the performance in comparison with double reading by experts.

The study will enroll women between 50 and 74 years old, at risk for lung cancer due to their smoking history.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Low-dose computed tomography of the chest
N/A

Detailed Description

Lung cancer is the leading cause of cancer death, worldwide. Several randomized studies have demonstrated that annual or biennial low-dose CT screening reduces lung cancer mortality. However, these studies involved expert chest radiologists, with double reading being performed in most studies. Furthermore, none of the published studies have evaluated the role of artificial intelligence to serve as second of concurrent reader.

Women with at least 25 pack-year smoking history who quitted smoking less than 15 years ago will be enrolled to have baseline, 1-year and 2-year low-dose CT of the chest.

The CT scans will be read on site by a general radiologist trained to lung cancer screening according to the European lung cancer screening certification program, first without then with the aid of an artificial algorithm trained to lung nodule detection (Veye Chest, Aidence). All CT scans will also be read by 2 chest experts, who will resolve their disagreement by a consensus reading if necessary. Patient management will rely on the double reading by expert. The criteria for positive screen result are as follows: solid nodule > 500 mm3 (10 mm) or growing (30% volume increase), part-solid nodule with > 8 mm solid component or new or growing, pure ground glass nodule developing a solid portion.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
2400 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Lung Cancer Screening With Low-dose CT Scan in Women : Implementation Study
Actual Study Start Date :
Apr 8, 2022
Anticipated Primary Completion Date :
Apr 8, 2024
Anticipated Study Completion Date :
Oct 8, 2024

Arms and Interventions

Arm Intervention/Treatment
Other: Procedure

Baseline low dose Ct acquisition, then at 1 year and 2 years to depict suspicious lung nodules

Procedure: Low-dose computed tomography of the chest
Baseline low dose Ct acquisition, then at 1 year and 2 years to depict suspicious lung nodules

Outcome Measures

Primary Outcome Measures

  1. Performance of trained radiologists for lung cancer screening [2 years]

    Sensitivity, specificity, predictive values compared to double reading by experts

Secondary Outcome Measures

  1. Effectiveness of screening [2 years]

    Proportion of participants with a positive screening test and proportion of confirmed diagnosis of cancer

  2. Analysis of the diagnostic performance of the reading without detection software, in order to assess its incremental value [2 years]

    Sensitivity, specificity, predictive values and likelihood ratios of the initial reading compared to the expert readings, using histological diagnosis as gold standard for positive screens and stability at 2 years for negative screens

  3. Analysis of the performance of a reading by detection software alone [2 years]

    Sensitivity, specificity, predictive values and likelihood ratios of artificial intelligence alone

  4. Analysis of the concordances of the different readings [2 years]

    Kappa concordance coefficient between the different readings

  5. Adherence to screening [2 years]

    Number of participants related to the number of eligible women, having completed all the required scans (3 to 6), speed of inclusion in the study

  6. Analysis of the impact of screening on smoking cessation [2 years]

    Smoking cessation rate at the end of the study

  7. Psychological impact of screening [2 years]

    HADS (Hospital Anxiety and Depression Scale) questionnaire at each scan, Cancer worry scale, Satisfaction with Decision scale at inclusion and end of study, all translated into French

  8. Number of co-morbidities (COPD, coronary artery disease) detected [2 years]

    Number of participants related to the number of women included in the study for whom treatment is initiated (bronchodilators/ statins or revascularization/ osteoporosis treatment)

  9. Evaluation of costs induced by screening [2 years]

    Cost measures: total cost of screening, average cost per woman, average cost per woman screened

  10. Prevalence of osteoporosis by opportunistic screening [2 years]

    Presence of at least one thoracic vertebral fracture and measurement of trabecular attenuation of the T8 vertebral body

Eligibility Criteria

Criteria

Ages Eligible for Study:
50 Years to 74 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Women aged from 50 to 74 years

  • who had smoked at least 20 pack years and quit less than 15 years ago

  • Had given their consent and accepted the need for a 2-year follow-up

  • Affiliated to the social security system

Exclusion Criteria

  • Presence of clinical symptoms suggesting malignancy (weight loss, hemoptysis) or ongoing infection (cough with fever)

  • Evolving cancer

  • History of lung cancer

  • A 2-year follow-up not possible

  • Chest CT scan performed within 2 years prior to inclusion

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hôtel-Dieu Paris France 75004

Sponsors and Collaborators

  • Assistance Publique - Hôpitaux de Paris
  • Ministère de la Santé et des Solidarités
  • National Cancer Institute, France

Investigators

  • Principal Investigator: Marie-Pierre REVEL, PhD, Assistance Publique - Hôpitaux de Paris
  • Principal Investigator: Marie WISLEZ, PhD, Assistance Publique - Hôpitaux de Paris

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier:
NCT05195385
Other Study ID Numbers:
  • APHP210362
  • 2021-A02265-36
First Posted:
Jan 19, 2022
Last Update Posted:
Jul 25, 2022
Last Verified:
May 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Assistance Publique - Hôpitaux de Paris
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 25, 2022